Patients
Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson's disease, rheumatoid arthritis, restless legs syndrome...
Top of this page
Skip navigation, go straight to the content
With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in two therapeutic areas - CNS and Immunology. UCB also has a selective presence in primary care.
Investors
With global revenue of more than €3 billion, we have a long track record of turning novel ideas into commercial realities...
Journalists
UCB aims to become the next generation biopharmaceutical leader, based on unique blending of innovation, entrepreneurship and experience, bringing breakthrough innovation and new medicines for patients suffering from severe disease.
Job seekers
Join us and make a world of difference as we build the next generation biopharma, supported by a dynamic team in over 40 countries across the globe...
Partners
A world leader in antibody research, plus a strong pipeline of large and small molecules, has attracted partners, such as Amgen...
